Imaging Rheumatoid Arthritis in Mice Using Combined Near Infrared and F Magnetic Resonance Modalities

Overview

Journal Sci Rep

Specialty Science

Date 2019 Oct 6

PMID 31586092

Citations 8

Authors

Hieu Vu-Quang

Mads Sloth Vinding

Maria Jakobsen

Ping Song

Frederik Dagnaes-Hansen

Niels Chr Nielsen

Jorgen Kjems

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that causes pain and tissue destruction in people worldwide. An accurate diagnosis is paramount in order to develop an effective treatment plan. This study demonstrates that combining near infrared (NIR) imaging and F MRI with the injection of labelled nanoparticles provides high diagnostic specificity for RA. The nanoparticles were made from poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (NP) or PLGA-PEG-Folate (Folate-NP), loaded with perfluorooctyl bromide (PFOB) and indocyanine green (ICG) and evaluated in vitro and in a collagen-induced arthritic (CIA) mouse model. The different particles had a similar size and a spherical shape according to dynamic light scattering (DLS) and transmission electron microscopy (TEM). Based on flow cytometry and F MRI analysis, Folate-NP yielded a higher uptake than NP in activated macrophages in vitro. The potential RA-targeting ability of the particles was studied in CIA mice using NIR and F MRI analysis. Both NP and Folate-NP accumulated in the RA tissues, where they were visible in NIR and F MRI for up to 24 hours. The presence of folate as a targeting ligand significantly improved the NIR signal from inflamed tissue at the early time point (2 hours), but not at later time points. Overall, these results suggest that our nanoparticles can be applied for combined NIR and F MRI imaging for improved RA diagnosis.

Citing Articles

Perfluorocarbons: A perspective of theranostic applications and challenges.

Kakaei N, Amirian R, Azadi M, Mohammadi G, Izadi Z Front Bioeng Biotechnol. 2023; 11:1115254.

PMID: 37600314 PMC: 10436007. DOI: 10.3389/fbioe.2023.1115254.

Nanomaterial-assisted theranosis of bone diseases.

Zheng K, Bai J, Yang H, Xu Y, Pan G, Wang H Bioact Mater. 2023; 24:263-312.

PMID: 36632509 PMC: 9813540. DOI: 10.1016/j.bioactmat.2022.12.014.

Nanotechnology as a Versatile Tool for F-MRI Agent's Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles.

Joseph J, Gigliobianco M, Mahdavi Firouzabadi B, Censi R, Di Martino P Pharmaceutics. 2022; 14(2).

PMID: 35214114 PMC: 8874484. DOI: 10.3390/pharmaceutics14020382.

Imaging of Inflammation in Spinal Cord Injury: Novel Insights on the Usage of PFC-Based Contrast Agents.

Garello F, Boido M, Miglietti M, Bitonto V, Zenzola M, Filippi M Biomedicines. 2021; 9(4).

PMID: 33916774 PMC: 8065995. DOI: 10.3390/biomedicines9040379.

Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.

Hosseinikhah S, Barani M, Rahdar A, Madry H, Arshad R, Mohammadzadeh V Int J Mol Sci. 2021; 22(6).

PMID: 33803502 PMC: 8002885. DOI: 10.3390/ijms22063092.

References

Bresnihan B . Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol. 1999; 26(3):717-9. View

Feldmann M, Brennan F, Maini R . Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996; 14:397-440. DOI: 10.1146/annurev.immunol.14.1.397. View

Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos C, Reddy J . Folate receptor-β in activated macrophages: ligand binding and receptor recycling kinetics. Mol Pharm. 2014; 11(10):3609-16. DOI: 10.1021/mp500348e. View

Pham C . Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011; 3(6):607-19. PMC: 3800699. DOI: 10.1002/wnan.157. View

Bilthariya U, Jain N, Rajoriya V, Jain A . Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev Ind Pharm. 2013; 41(1):95-104. DOI: 10.3109/03639045.2013.850705. View

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

Altinoglu E, Adair J . Near infrared imaging with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2(5):461-77. DOI: 10.1002/wnan.77. View

Saxena V, Sadoqi M, Shao J . Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int J Pharm. 2004; 278(2):293-301. DOI: 10.1016/j.ijpharm.2004.03.032. View

Esmaeili F, Ghahremani M, Ostad S, Atyabi F, Seyedabadi M, Malekshahi M . Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008; 16(5):415-23. DOI: 10.1080/10611860802088630. View

10.

Yoo H, Park T . Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004; 96(2):273-83. DOI: 10.1016/j.jconrel.2004.02.003. View

11.

Frangioni J . In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003; 7(5):626-34. DOI: 10.1016/j.cbpa.2003.08.007. View

12.

Feng H, Zhang Z, Meng Q, Jia H, Wang Y, Zhang R . Rapid Response Fluorescence Probe Enabled In Vivo Diagnosis and Assessing Treatment Response of Hypochlorous Acid-Mediated Rheumatoid Arthritis. Adv Sci (Weinh). 2018; 5(8):1800397. PMC: 6096987. DOI: 10.1002/advs.201800397. View

13.

Diaz-Lopez R, Tsapis N, Fattal E . Liquid perfluorocarbons as contrast agents for ultrasonography and (19)F-MRI. Pharm Res. 2009; 27(1):1-16. DOI: 10.1007/s11095-009-0001-5. View

14.

Brown J, Duncan J, Heiken J, Balfe D, Corr A, Mirowitz S . Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon. Radiology. 1991; 181(2):455-60. DOI: 10.1148/radiology.181.2.1924788. View

15.

Liu M, Long D . Perfluoroctylbromide as a diagnostic contrast medium in gastroenterography. Radiology. 1977; 122(1):71-6. DOI: 10.1148/122.1.71. View

16.

Diou O, Tsapis N, Giraudeau C, Valette J, Gueutin C, Bourasset F . Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI. Biomaterials. 2012; 33(22):5593-602. DOI: 10.1016/j.biomaterials.2012.04.037. View

17.

Ahrens E, Helfer B, OHanlon C, Schirda C . Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med. 2014; 72(6):1696-701. PMC: 4253123. DOI: 10.1002/mrm.25454. View

18.

Zhou H, Yan H, Senpan A, Wickline S, Pan D, Lanza G . Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials. 2012; 33(33):8632-40. PMC: 3583210. DOI: 10.1016/j.biomaterials.2012.08.005. View

19.

McQueen F . Magnetic resonance imaging in early inflammatory arthritis: what is its role?. Rheumatology (Oxford). 2000; 39(7):700-6. DOI: 10.1093/rheumatology/39.7.700. View

20.

Mohd Noor N, Mohd Shahrir M, Shahid M, Abdul Manap R, Shahizon Azura A, Shah S . Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis. 2010; 12(2):136-44. DOI: 10.1111/j.1756-185X.2009.01376.x. View